Cover Image
Market Research Report

Anti-infective Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

Published by Mordor Intelligence LLP Product code 911977
Published Content info 114 Pages
Delivery time: 2-3 business days
Price
Back to Top
Anti-infective Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)
Published: June 1, 2020 Content info: 114 Pages
Description

Anti-infectives drugs has been one of the major segment for many pharmaceutical companies from decades. Over the past two decades, the infection rate has grown significantly, particularly across the low and middle income countries.

There are a large number of companies well-established in the market with their products in the form of antifungals, antibiotics, anti-bacterial, anti-protozoans and antivirals targeting cytochrome, interleukin, interferons and some are multi-drug resistants. The primary driving factor for the growth of the market is increasing burden of several infectious diseases across developed and emerging markets such as different forms of influenza, diarrhea, hepatitis, and urinary tract infections, among others, which needs more attention from pharmaceutical and biotechnology companies.

Moreover, there has been significant growth in the number of multidrug-resistant organisms across several parts of the world, which further increases the importance of innovation in the anti-infective agents.

However, some of the major restraints to this market are high investment costs in R&D, as major importance is given to multi-drug resistant drug, where several companies product fail in the early-stage or clinical stage of development. Also, shortage of resources in healthcare facilities particularly in emerging markets, restricts the growth of this market.

Key Market Trends

Antiviral Products are Expected to Register High Growth Over the Forecast Period

  • The anti-viral agents are expected to show high growth over the forecast period, as several drug manufacturers are exploring the opportunities to expand in the lower and middle income countries, where epidemic infection rate is high.
  • There is high diversity in patient pool which require long treatment procedures in hospital facilities as well as home care treatments.
  • Moreover, there has been observed a growing interest by government in countries showing fast economic growth, to collaborate with hospitals and global pharmaceutical companies to imporve the distribution rate of antiviral agents to the needful in the required area of a country. Such factors are expected to boost the growth of antivirals segment over the forecast period.

North America is Estimated to Have Largest Share Over the Forecast Period

With a sophisticated healthcare infrastructure, high awareness in the society, well-established distribution channels and good presence of e-commerce across the United States and Canada drives, helps North America to dominate this market over the forecast period.

The high purchasing power by the end consumer and favorable reimbursement policies helps pharmaceutical companies to grow in this region. Further, it helps the pharmacetical companies increase the production capabilities, invest more upon the funded projects with renowned medical institutions to suffice the demand of anti-infective drugs across North America.

Competitive Landscape

The major market players are focusing on better distribution channel as well as reaching out to each category of patients with different diseases and age groups, which makes the companies grow in this market. Some of the major players in the market are Novartis AG, Merck & Co., Inc, Sanofi SA, GSK, and Gilead Sciences, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Table of Contents
Product Code: 66831

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Targeted Diseases
    • 4.2.2 Growing Initiatives for the Awareness of Infectious Diseases
    • 4.2.3 Increasing Investments on R&D Activities of Anti-Infective Drugs
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Side Effects Associated with Anti-infective drugs
    • 4.3.2 Shortage of Resources in Certain Low- and Middle-income Countries (LMIC)
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Antibiotics
    • 5.1.2 Antivirals
    • 5.1.3 Antifungals
    • 5.1.4 Other Products
  • 5.2 By Indication
    • 5.2.1 HIV Infection
    • 5.2.2 Pneumonia
    • 5.2.3 Respiratory Virus Infection
    • 5.2.4 Sepsis
    • 5.2.5 Tuberculosis
    • 5.2.6 Other Indications
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacy
    • 5.3.2 Retail Pharmacy
    • 5.3.3 Other Distribution Channels
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 France
      • 5.4.2.2 Germany
      • 5.4.2.3 United Kingdom
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Astellas Pharma Inc
    • 6.1.3 Bayer AG
    • 6.1.4 Bristol-Myers Squibb Company
    • 6.1.5 Gilead Sciences, Inc
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Merck & Co., Inc.
    • 6.1.8 Novartis AG
    • 6.1.9 Pfizer, Inc
    • 6.1.10 Sanofi SA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top